Lexaria Bioscience (LEXX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$194,000.00

Revenue (quarter)

—

Revenue growth (year over year)

−100.00%

Gross profit (trailing twelve months)

$194,000.00

Gross margin

100.00%

Net income (trailing twelve months)

−$7.7M

Net income (quarter)

−$2.0M

Net income growth (year over year)

+47.42%

Net margin

−3989.92%

Return on equity

−150.28%

EPS (trailing twelve months)

−$3.28

Book value per share

$2.87

P/E (trailing twelve months)

—

Price to book

1.37

Debt to assets

9.14%

Payout ratio

—

Dividend yield

—

Company profile

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

• Is Lexaria Bioscience (LEXX) profitable?

  No. Lexaria Bioscience reported a net loss of $7.7M over the trailing twelve months.

• How much revenue does Lexaria Bioscience (LEXX) make?

  Lexaria Bioscience generated $194,000.00 in revenue over the trailing twelve months, down 100.00% year over year.

• How do I buy stock in Lexaria Bioscience (LEXX)?

  LEXX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.